Ibere Pharmaceuticals
CIK 0001835205
Revenue (TTM)
—
Q3 Sep 2022
Net Income (TTM)
$7.57M
+27,218.4% YoY
Q3 Sep 2022
EPS Diluted (TTM)
—
Q3 Sep 2022
Gross Margin
—
Q3 Sep 2022
Operating Margin
—
Q3 Sep 2022
Net Margin
—
Q3 Sep 2022
Free Cash Flow (TTM)
—
Q3 Sep 2022
Cash
$4.45K
Q3 Sep 2022
Total Debt
$0
Q3 Sep 2022
Shares Outstanding
—
Q3 Sep 2022
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.